Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Biohaven Pharmaceutical Holding Company Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK , AUG. 14, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF BIOHAVEN LTD. (NYSE: BHVN).

BIOHAVEN LTD. SUED FOR SECURITIES LAW VIOLATIONS - INVESTORS SHOULD CONTACT THE GROSS LAW FIRM FOR MORE INFORMATION - BHVN

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN BIOHAVEN TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

SHAREHOLDER ACTION REMINDER: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF BIOHAVEN

NEW YORK, AUG. 11, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN BIOHAVEN LTD. ("BIOHAVEN LTD." OR THE "COMPANY") (NYSE: BHVN) OF A CLASS ACTION SECURITIES LAWSUIT.

BIOHAVEN LTD. SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT LEVI & KORSINSKY BEFORE SEPTEMBER 12, 2025 TO DISCUSS YOUR RIGHTS  BHVN

CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND RESTRICTED CASH AS OF JUNE 30, 2025, TOTALED APPROXIMATELY $408.2 MILLION VYGLXIA NDA FOR SPINOCEREBELLAR ATAXIA (SCA) PDUFA DATE 4Q2025, COMPLETED CLINICAL TRIAL INSPECTIONS BY FDA WITHOUT OBSERVATIONS OR FINDINGS, AND FILING REVIEW REMAINS ONGOING MODE AND TRAP DEGRADER PLATFORMS ADVANCE IN CLINICAL DEVELOPMENT, IGG REDUCTIONS OF UP TO 87% OBSERVED WITH MODE DEGRADER BHV-1300 IN PHASE 1 WITH THE POTENTIAL TO ADDRESS IGG-MEDIATED DISEASES INCLUDING GRAVES' DISEASE AND RHEUMATOID ARTHRITIS; SUSTAINED AND DEEP GD-IGA1 REDUCTIONS OVER 80% REPORTED WITH TRAP DEGRADER BHV-1400 HIGHLIGHT ITS POTENTIAL FOR TREATING IGA NEPHROPATHY NEXT -GENERATION TROP2 ANTIBODY DRUG CONJUGATE (ADC) BHV-1510 DEMONSTRATED EARLY CLINICAL ACTIVITY, FAVORABLE PK AND DIFFERENTIATED SAFETY PROFILE IN A PHASE 1/2 STUDY AS A MONOTHERAPY AND IN COMBINATION WITH REGENERON'S ANTI-PD-1 CEMIPLIMAB (LIBTAYO); TUMOR REDUCTION WAS OBSERVED IN FIRST 6 OUT OF 6 PATIENTS TREATED WITH BHV-1510 PLUS CEMIPLIMAB INCLUDING CONFIRMED PARTIAL RESPONSES COMMENCED DOSING WITH BHV-1530, A NOVEL FGFR3-DIRECTED ADC WITH POTENTIAL APPLICATION IN UROTHELIAL CANCERS AND OTHER FGFR3-EXPRESSING SOLID TUMORS COMPASSIONATE USE OF OPAKALIM (BHV-7000) IN A CHILD WITH INTRACTABLE EPILEPSY DUE TO KV7 GENE MUTATION (KCNQ2 DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY [KCNQ2-DEE]) PROVIDES EARLY EVIDENCE OF POTENTIAL CLINICAL BENEFIT ASSOCIATED WITH BIOHAVEN'S NEXT-GENERATION KV7 ACTIVATOR ENROLLED FIRST PATIENT IN PIVOTAL PHASE 2/3 STUDY IN PARKINSON'S DISEASE (PD) WITH BHV-8000, A HIGHLY SELECTIVE, BRAIN-PENETRANT TYK2/JAK1 INHIBITOR WITH THE POTENTIAL TO MODULATE CRITICAL INFLAMMATORY PATHWAYS THAT UNDERPIN THE WIDESPREAD IMMUNE DYSREGULATION AND NEURODEGENERATION THAT DRIVE FUNCTIONAL DECLINE IN PEOPLE WITH PD NEW HAVEN, CONN. , AUG. 11, 2025 /PRNEWSWIRE/ -- BIOHAVEN LTD.

BIOHAVEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN BIOHAVEN TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN BIOHAVEN BETWEEN MARCH 24, 2023 AND MAY 14, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , AUG. 8, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST BIOHAVEN LTD.

NEW YORK , AUG. 7, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OFBIOHAVEN LTD. (NYSE: BHVN).

BIOHAVEN LTD. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE GROSS LAW FIRM BEFORE SEPTEMBER 12, 2025 TO DISCUSS YOUR RIGHTS - BHVN

NEW YORK, AUG. 06, 2025 (GLOBE NEWSWIRE) -- THE LAW FIRM OF KIRBY MCINERNEY LLP REMINDS INVESTORS THAT A CLASS ACTION LAWSUIT HAS BEEN FILED IN THE U.S. DISTRICT COURT FOR THE DISTRICT OF CONNECTICUT ON BEHALF OF THOSE WHO ACQUIRED BIOHAVEN LTD. (BIOHAVEN OR THE COMPANY) (NYSE:BHVN) SECURITIES DURING THE PERIOD OF MARCH 24, 2023 THROUGH MAY 14, 2025, INCLUSIVE (THE CLASS PERIOD). INVESTORS HAVE UNTIL SEPTEMBER 12, 2025 TO APPLY TO THE COURT TO BE AP-POINTED AS LEAD PLAINTIFF IN THE LAWSUIT.

BHVN INVESTORS: KIRBY MCINERNEY LLP REMINDS BIOHAVEN LTD. INVESTORS OF IMPORTANT DEADLINE AND ENCOURAGES INVESTORS TO CONTACT THE FIRM

NEW YORK, AUG. 05, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN BIOHAVEN LTD. ("BIOHAVEN LTD." OR THE "COMPANY") (NYSE: BHVN) OF A CLASS ACTION SECURITIES LAWSUIT.

BIOHAVEN LTD. SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT LEVI & KORSINSKY FOR MORE INFORMATION  BHVN

INVESTORS CAN CONTACT THE LAW FIRM AT NO COST TO LEARN MORE ABOUT RECOVERING THEIR LOSSES

BIOHAVEN LTD. INVESTORS: PLEASE CONTACT THE PORTNOY LAW FIRM TO RECOVER YOUR LOSSES.

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $50,000 IN BIOHAVEN TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

SHAREHOLDER REMINDER: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF BIOHAVEN

NEW YORK, JULY 31, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN BIOHAVEN LTD. ("BIOHAVEN LTD." OR THE "COMPANY") (NYSE: BHVN) OF A CLASS ACTION SECURITIES LAWSUIT.

SHAREHOLDERS OF BIOHAVEN LTD. SHOULD CONTACT LEVI & KORSINSKY BEFORE SEPTEMBER 12, 2025 TO DISCUSS YOUR RIGHTS  BHVN

NEW YORK, JULY 30, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF BIOHAVEN LTD. (NYSE: BHVN).

INVESTORS IN BIOHAVEN LTD. SHOULD CONTACT THE GROSS LAW FIRM BEFORE SEPTEMBER 12, 2025 TO DISCUSS YOUR RIGHTS  BHVN

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $50,000 IN BIOHAVEN TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED LOSSES EXCEEDING $50,000 IN BIOHAVEN BETWEEN MARCH 24, 2023 AND MAY 14, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , JULY 29, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST BIOHAVEN LTD.

INVESTOR DEADLINE APPROACHING: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF BIOHAVEN

NEW YORK , JULY 29, 2025 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN BIOHAVEN LTD. ("BIOHAVEN LTD.

SHAREHOLDERS OF BIOHAVEN LTD. SHOULD CONTACT LEVI & KORSINSKY BEFORE SEPTEMBER 12, 2025 TO DISCUSS YOUR RIGHTS - BHVN

NEW YORK , JULY 24, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF BIOHAVEN LTD. (NYSE: BHVN).

SHAREHOLDERS OF BIOHAVEN LTD. SHOULD CONTACT THE GROSS LAW FIRM BEFORE SEPTEMBER 12, 2025 TO DISCUSS YOUR RIGHTS - BHVN

NEW YORK , JULY 16, 2025 /PRNEWSWIRE/ --ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES THAT A SHAREHOLDER FILED A CLASS ACTION ON BEHALF OF PURCHASERS OF SECURITIES OFBIOHAVEN LTD. (NYSE: BHVN) BETWEEN MARCH 24, 2023 AND MAY 14, 2025.

ROSEN LAW FIRM URGES BIOHAVEN LTD. (NYSE: BHVN) STOCKHOLDERS TO CONTACT THE FIRM FOR INFORMATION ABOUT THEIR RIGHTS

DEADLINE ALERT: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF BIOHAVEN

NEW YORK--(BUSINESS WIRE)--ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES THAT A SHAREHOLDER FILED A CLASS ACTION ON BEHALF OF PURCHASERS OF SECURITIES OF BIOHAVEN LTD. (NYSE: BHVN) BETWEEN MARCH 24, 2023 AND MAY 14, 2025. BIOHAVEN DESCRIBES ITSELF AS A BIOPHARMACEUTICAL COMPANY THAT DISCOVERS, DEVELOPS, AND COMMERCIALIZES THERAPIES FOR IMMUNOLOGY, NEUROSCIENCE, AND ONCOLOGY. FOR MORE INFORMATION, SUBMIT A FORM, EMAIL ATTORNEY PHILLIP KIM, OR GIVE US A CALL AT 866-767-3653. THE.

NEW YORK, JUNE 28, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF BIOHAVEN LTD. (BIOHAVEN OR THE COMPANY) (NYSE: BHVN).

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMSON BEHALF OF INVESTORS OF BIOHAVEN LTD. - BHVN

NEW YORK, JUNE 23, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF BIOHAVEN LTD. (BIOHAVEN OR THE COMPANY) (NYSE: BHVN). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK , JUNE 22, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF BIOHAVEN LTD.("BIOHAVEN" OR THE "COMPANY") (NYSE: BHVN).

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF BIOHAVEN LTD. - BHVN

NEW YORK, JUNE 18, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF BIOHAVEN LTD. (BIOHAVEN OR THE COMPANY) (NYSE: BHVN).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK, JUNE 15, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF BIOHAVEN LTD. (BIOHAVEN OR THE COMPANY) (NYSE: BHVN).

NEW YORK, NY / ACCESS NEWSWIRE / JUNE 13, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF BIOHAVEN LTD. ("BIOHAVEN" OR THE "COMPANY") (NYSE:BHVN).

NEW YORK , JUNE 12, 2025 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF BIOHAVEN LTD.("BIOHAVEN" OR THE "COMPANY") (NYSE: BHVN).

NEW YORK CITY, NY / ACCESS NEWSWIRE / JUNE 11, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF BIOHAVEN LTD. ("BIOHAVEN" OR THE "COMPANY") (NYSE:BHVN).

Biohaven Pharmaceutical Holding Company Ltd.

BHVN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Biohaven Pharmaceutical Holding Company Ltd.

BHVN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BHVN